Clinical trials: Unresectable
Stomach Neoplasms
Irreversible Electroporation(IRE) For Unresectable Stomach Neoplasms
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Stomach Neoplasms.
- Trial name
- IRE (NCT02430636)
- Testing
- Irreversible electroporation (IRE), NanoKnife
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Hepatocellular Carcinoma
HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC
The treatment options for unresectable HCC have rapidly developed, and immunotherapy has shown significant survival benefits in hepatocellular carcinoma.
- Trial name
- NCT06364007
- Testing
- HAIC+STRIDE+Len
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sulai Liu
Neuroendocrine Tumors
Liver Transplantation Versus Conventional Medical Therapy for Low-Grade GEP-NET With Liver Metastases
Liver Transplantation Versus Conventional Medical Therapy for Low-Grade GEP-NET With Liver Metastases
- Trial name
- TRANET-GEP (NCT07913113)
- Testing
- Liver Transplantation
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Chiyi Chen
Carcinoma, Hepatocellular
Associating Liver Partition With Portal Vein Ligation For Staged Hepatectomy (ALPPS) or Portal Vein Occlusion in Treating Patients With Liver Cancer
This randomized phase II trial compares how well associating liver partition with portal vein ligation for staged hepatectomy (ALPPS) or portal vein occlusion (PVO) works in treating patients with liver cancer.
- Trial name
- ALPPS (NCT01722175)
- Testing
- ALPPS surgery, PVO surgery
- Volunteers
- healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Stage IV Melanoma, Advanced Lung Cancer
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
The purpose of this study is to refine and pilot test educational material developed to educate and support patients receiving immunotherapy for advanced cancer.
- Conditions
- Stage IV Melanoma, Advanced Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Non-Small Cell Lung Carcinoma
- Trial name
- UPLIFT (NCT04670445)
- Testing
- Educational Video and QPL List, Usual Care
- Where
- United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Breast Cancer, Colorectal Cancer
UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer
RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer and blood from healthy participants may help doctors learn more about changes that may occur in DNA and identify biomarkers related…
- Conditions
- Breast Cancer, Colorectal Cancer, Esophageal Cancer, Liver Cancer
- Trial name
- IRB 2000-294 (NCT00900094)
- Testing
- fluorescence in situ hybridization, polymerase chain reaction, protein expression analysis
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Michigan Rogel Cancer Center
Pancreatic Adenocarcinoma Non-resectable
EUS-RFA for Unresectable Pancreatic Ductal Adenocarcinoma
the study evaluate the efficacy and safety of EUS-RFA using Habib EUS-RFA catheter with a prospective randomised trial in patients with inoperable PDAC.
- Trial name
- NCT03772756
- Testing
- Endoscopic ultrasound guided radiofrequency ablation, chemoradiotherapy
- Where
- 2 sites in China
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- First People's Hospital of Hangzhou
Melanoma, BRAF V600 Mutation
Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations
The current commercially available MEKTOVI® (binimetinib) 15 mg tablets are provided as immediate release film-coated tablets for oral administration.
- Conditions
- Melanoma, BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma
- Trial name
- NCT05810740
- Testing
- Binimetinib 15 MG, Binimetinib 45 MG
- Where
- France
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Medicament
Melanoma, BRAF V600 Mutation
Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations
The current commercially available MEKTOVI® (binimetinib) 15 mg tablets are provided as immediate release film-coated tablets for oral administration.
- Conditions
- Melanoma, BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma
- Trial name
- NCT05103891
- Testing
- Binimetinib Oral Tablet
- Where
- France
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Medicament
Metastatic Penile Squamous Cell Carcinoma, Stage III Penile Cancer AJCC v8
Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis
This phase II trial tests how well enfortumab vedotin works for treating patients with squamous cell carcinoma of the penis that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable).
- Conditions
- Metastatic Penile Squamous Cell Carcinoma, Stage III Penile Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Unresectable Penile Squamous Cell Carcinoma
- Trial name
- NCT06104618
- Testing
- Enfortumab Vedotin, Computed Tomography, Magnetic Resonance Imaging
- Where
- 3 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Locally Advanced Bladder Carcinoma, Metastatic Bladder Carcinoma
An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers
This clinical trial evaluates the impact of an education and navigation support tool (ENST) on patient and caregiver participation in care coordination for bladder cancer that has spread to nearby tissue or lymph nodes (locally…
- Conditions
- Locally Advanced Bladder Carcinoma, Metastatic Bladder Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8
- Trial name
- NCT06414317
- Testing
- Assessment of Distress, Consultation Visit, Nutritional Assessment
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Roswell Park Cancer Institute
Laryngeal Neoplasms
Irreversible Electroporation(IRE) For Unresectable Laryngeal Neoplasms
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Laryngeal Neoplasms.
- Trial name
- IRE (NCT02430675)
- Testing
- Irreversible electroporation (IRE), NanoKnife
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Esophageal Squamous Cell Carcinoma by AJCC V8 Stage, Unresectable
Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell Carcinoma
Whether the introduction of immunotherapy can transform unresectable esophageal cancer into resectable, or even achieve R0 surgical resection, has not been reported yet.
- Trial name
- NCT05449483
- Testing
- tislelizumab+ Paclitaxel + Cisplatin
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Safety and Efficacy
Study on the Safety and Efficacy of MR-Linac Technique in Patients With Unresectable Locally Advanced Colon Cancer
In this phase I single-arm clinical study, 20 patients with T4 unresectable locally advanced colon cancer are proposed to be enrolled, who will be treated with MR-Linac with short course radiotherapy (25Gy/5F), followed by 4…
- Trial name
- UNLACC (NCT06244537)
- Testing
- MR-linac
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Immunotherapy, Intensity Modulated Radiation Therapy
Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Simultaneous radiotherapy followed by adjuvant immunotherapy is the standard treatment modality of unresectable stage III NSCLC.
- Conditions
- Immunotherapy, Intensity Modulated Radiation Therapy, Radiotherapy, NSCLC
- Trial name
- NCT05909137
- Testing
- IMRT+adjuvant immunotherapy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Xinqiao Hospital of Chongqing
Extremities Neoplasms
Irreversible Electroporation(IRE) For Unresectable Extremities Neoplasms
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Extremities Neoplasms.
- Trial name
- IRE (NCT02430688)
- Testing
- Irreversible electroporation (IRE), NanoKnife
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Hilus Pulmonary Neoplasms
Irreversible Electroporation(IRE) For Unresectable Hilus Pulmonis Neoplasms
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for Hilus Pumonis Neoplasms.
- Trial name
- IRE (NCT02430597)
- Testing
- Irreversible electroporation (IRE), NanoKnife
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Renal Pelvic and Ureteral Neoplasms
Irreversible Electroporation(IRE) For Unresectable Renal Pelvic and Ureteral Neoplasms
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Renal Pelvic and Ureteral Neoplasms.
- Trial name
- IRE (NCT02430779)
- Testing
- rreversible electroporation (IRE), NanoKnife
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Uterine Cervical Neoplasms
Irreversible Electroporation(IRE) For Uterine Cervical Neoplasms
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Uterine Cervical Neoplasms.
- Trial name
- IRE (NCT02430610)
- Testing
- Irreversible electroporation (IRE), NanoKnife
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Lymph Node Metastases
Irreversible Electroporation(IRE) For Unresectable Lymph Node Metastases(Close to Nerve)
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Lymph Node Metastases.
- Trial name
- IRE (NCT02430766)
- Testing
- Irreversible electroporation (IRE), NanoKnife
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou